Neurocrine Biosciences Inc. (N1BI34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 39.20 |
|---|---|
| 52-week range | 31.51 – 45.78 |
| Return, 1 month / 3 months | +8.9% / −11.9% |
| Return, 1 year / 3 years | +1.9% / +46.3% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 33.8% |
| Worst drawdown (1 year) | -25.1% |
| Average daily value traded | 0.06M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Neurocrine Biosciences is a biopharmaceutical company based in San Diego, California, that discovers and develops medicines for neurological, psychiatric and endocrine conditions. Its products treat movement disorders such as tardive dyskinesia and Huntington's disease chorea, and it also offers treatments for endometriosis-related pain. The company serves patients and healthcare providers, mainly through specialty pharmacies and physicians in the United States, and it conducts research on disorders of the nervous and hormonal systems.
Neurocrine Biosciences Inc. is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code N1BI34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Neurocrine Biosciences Inc. (N1BI34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 39.20 on 27 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 776 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 1.9% and over the last three months it fell 11.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.3% | ||
| From 52-week high | -14.4% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -11.9% | ||
| 6-month return | 24.0% | ||
| 12-month return, skipping the last month | -6.4% | ||
| Stability (higher is calmer) | 61 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 33.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -25.1% | ||
| Liquidity | 38 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.06M BRL | ||
| Zero-volume days | 40.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +9.6% |
|---|---|
| 1 month | +8.9% |
| 3 months | −11.9% |
| 6 months | +24.0% |
| 1 year | +1.9% |
| 3 years | +46.3% |
| 5 years | – |
Signals
| 50-day / 200-day average | 38.05 / 37.95 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.77 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.